Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 338

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

Open access
Swain, Sandra M., Jeong, Jong-Hyeon, Geyer, Charles E., Costantino, Joseph P., Pajon, Eduardo R., Fehrenbacher, Louis, Atkins, James N., Polikoff, Jonathan, Vogel, Victor G., Erban, John K., Rastogi, Priya, Livingston, Robert B., Perez, Edith A., Mamounas, Eleftherios P., Land, Stephanie R., Ganz, Patricia A., Wolmark, Norman·2010·New England Journal of Medicine

Abstract

BACKGROUND: Chemotherapy regimens that combine anthracyclines and taxanes result in improved disease-free and overall survival among women with operable lymph-node-positive breast cancer. The effectiveness of concurrent versus sequential regimens is not known. METHODS: We randomly assigned 5351 patients with operable, node-positive, early-stage breast cancer to receive four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (sequential ACT); four cycles of doxorubicin and docetaxel (doxorubicin-docetaxel); or four cycles of doxorubicin, cyclophosphamide, and docetaxel (concurrent ACT). The primary aims were to examine whether concurrent ACT was more effective than sequential ACT and whether the doxorubicin-docetaxel regimen would be as effective as the concurrent-ACT regimen. The secondary aims were to assess toxic effects and to correlate amenorrhea with outcomes in premenopausal women. RESULTS: At a median follow-up of 73 months, overall survival was improved in the sequential-ACT group (8-year overall survival, 83%) as compared with the doxorubicin-docetaxel group (overall survival, 79%; hazard ratio for death, 0.83; P=0.03) and the concurrent-ACT group (overall survival, 79%; hazard ratio, 0.86; P=0.09). Disease-free survival was improved in the sequential-ACT group (8-year disease-free survival, 74%) as compared with the doxorubicin-docetaxel group (disease-free survival, 69%; hazard ratio for recurrence, a second malignant condition, or death, 0.80; P=0.001) and the concurrent-ACT group (disease-free survival, 69%; hazard ratio, 0.83; P=0.01). The doxorubicin-docetaxel regimen showed noninferiority to the concurrent-ACT regimen for overall survival (hazard ratio, 0.96; 95% confidence interval, 0.82 to 1.14). Overall survival was improved in patients with amenorrhea for 6 months or more across all treatment groups, independently of estrogen-receptor status. CONCLUSIONS: Sequential ACT improved disease-free survival as compared with doxorubicin-docetaxel or concurrent ACT, and it improved overall survival as compared with doxorubicin-docetaxel. Amenorrhea was associated with improved survival regardless of the treatment and estrogen-receptor status. (ClinicalTrials.gov number, NCT00003782.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0909638

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 338

Metadata

Authors
Swain, S. M., Jeong, J.-H., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., Atkins, J. N., Polikoff, J., Vogel, V. G., Erban, J. K., Rastogi, P., Livingston, R. B., Perez, E. A., Mamounas, E. P., Land, S. R., Ganz, P. A., & Wolmark, N.
Venue
New England Journal of Medicine
Published
2010-06-03
Volume
362
Issue
22
Pages
2053-2065
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2089265205
Cited by
338
References
20
FWCI
8.94
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. https://app.cochat.ai/papers/10.1056/nejmoa0909638
The paper
Swain, S. M., Jeong, J.-H., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., Atkins, J. N., Polikoff, J., Vogel, V. G., Erban, J. K., Rastogi, P., Livingston, R. B., Perez, E. A., Mamounas, E. P., Land, S. R., Ganz, P. A., & Wolmark, N. (2010). Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa0909638

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.